Alterations of the histone methyltransferase SETD2 are also correlated with prognosis in renal cell cancer and may be involved in resistance to chemotherapy in breast cancer, as was observed with paclitaxel in our study [51, 52]. The gene discussed is SETD2; the disease is renal cell adenocarcinoma.